再鼎医药(09688)股价涨超10%,一季度总收入同比增长22.19%至1.06亿美元,产品收入净额同比增长21%。公司正在进行的DLL3 ADC全球1a/1b期临床研究最新数据将在2025年美国临床肿瘤学会(ASCO)年会上公布。浦银国际建议重点关注该药物在ASCO大会上的数据更新及潜在出海机会。预计ZL-1310 (DLL3 ADC)将在ASCO大会上公布约70个病人的2L+ SCLC一期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.